Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (61-70 of 192) with videos related to

Pageof 20
Sort By:
AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.
AIDS Reviews|August 8, 2014
Novel antiretroviral drugs and renal function monitoring of HIV patientsPaolo Maggi, Vincenzo Montinaro, Cristina Mussini, et al.
AIDS (London, England)|February 14, 2006
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patientsDaniela Mologni, Paola Citterio, Barbara Menzaghi, et al.
Infection|September 4, 2025
Use of fexinidazole in gambiense human African trypanosomiasis: a retrospective analysis of cases treated in Lui Hospital, South Sudan (2018-2024)Francesca Mariotti, Riccardo Paggi, Matteo Basilico, et al.
Drug Design, Development and Therapy|May 27, 2016
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional studyAndrea Antinori, Paola Meraviglia, Antonella d'Arminio Monforte, et al.
Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.
The Journal of Infection|September 14, 2010
Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in BissauErika Gianelli, Agostino Riva, Fanny A Rankin Bravo, et al.
AIDS (London, England)|July 25, 2014
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety resultsAntonella Castagna, Vincenzo Spagnuolo, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|July 13, 2024
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Domenico Pontillo, Tommaso Clemente, et al.
Journal of the International AIDS Society|November 15, 2014
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA studyRoberta Gagliardini, Barbara Rossetti, Claudia Bianco, et al.
Pageof 20

Showing results (61-70 of 192) with videos related to

Sort By:
Pageof 20
AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.
AIDS Reviews|August 8, 2014
Novel antiretroviral drugs and renal function monitoring of HIV patientsPaolo Maggi, Vincenzo Montinaro, Cristina Mussini, et al.
AIDS (London, England)|February 14, 2006
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patientsDaniela Mologni, Paola Citterio, Barbara Menzaghi, et al.
Infection|September 4, 2025
Use of fexinidazole in gambiense human African trypanosomiasis: a retrospective analysis of cases treated in Lui Hospital, South Sudan (2018-2024)Francesca Mariotti, Riccardo Paggi, Matteo Basilico, et al.
Drug Design, Development and Therapy|May 27, 2016
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional studyAndrea Antinori, Paola Meraviglia, Antonella d'Arminio Monforte, et al.
Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.
The Journal of Infection|September 14, 2010
Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in BissauErika Gianelli, Agostino Riva, Fanny A Rankin Bravo, et al.
AIDS (London, England)|July 25, 2014
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety resultsAntonella Castagna, Vincenzo Spagnuolo, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|July 13, 2024
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Domenico Pontillo, Tommaso Clemente, et al.
Journal of the International AIDS Society|November 15, 2014
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA studyRoberta Gagliardini, Barbara Rossetti, Claudia Bianco, et al.
Pageof 20